PL3389653T3 - 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych - Google Patents
2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowychInfo
- Publication number
- PL3389653T3 PL3389653T3 PL16825913.3T PL16825913T PL3389653T3 PL 3389653 T3 PL3389653 T3 PL 3389653T3 PL 16825913 T PL16825913 T PL 16825913T PL 3389653 T3 PL3389653 T3 PL 3389653T3
- Authority
- PL
- Poland
- Prior art keywords
- iminobiotin
- treatment
- brain cell
- cell injury
- injury
- Prior art date
Links
- WWVANQJRLPIHNS-BKPPORCPSA-N 2-iminobiotin Chemical compound N1C(=N)N[C@H]2[C@H](CCCCC(=O)O)SC[C@H]21 WWVANQJRLPIHNS-BKPPORCPSA-N 0.000 title 1
- 210000004958 brain cell Anatomy 0.000 title 1
- 230000005779 cell damage Effects 0.000 title 1
- 208000037887 cell injury Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200492 | 2015-12-16 | ||
| PCT/NL2016/050880 WO2017105237A1 (en) | 2015-12-16 | 2016-12-16 | 2-iminobiotin for use in the treatment of brain cell injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3389653T3 true PL3389653T3 (pl) | 2024-02-26 |
Family
ID=54936830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16825913.3T PL3389653T3 (pl) | 2015-12-16 | 2016-12-16 | 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10525039B2 (pl) |
| EP (1) | EP3389653B1 (pl) |
| JP (1) | JP6975165B2 (pl) |
| AU (1) | AU2016372396B2 (pl) |
| CA (1) | CA3008790A1 (pl) |
| DK (1) | DK3389653T3 (pl) |
| ES (1) | ES2965754T3 (pl) |
| FI (1) | FI3389653T3 (pl) |
| PL (1) | PL3389653T3 (pl) |
| PT (1) | PT3389653T (pl) |
| WO (1) | WO2017105237A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3389653T3 (da) | 2015-12-16 | 2024-01-02 | Neurophyxia B V | 2-iminobiotin til anvendelse i behandling af hjernecellelæsion |
| WO2019157277A1 (en) * | 2018-02-09 | 2019-08-15 | Yale University | Methods, systems and compositions for normothermic ex vivo restoration and preservation of intact organs |
| WO2022203505A1 (en) * | 2021-03-23 | 2022-09-29 | Neurophyxia B.V. | 2-iminobiotin for use in the treatment of stroke |
| IL306094A (en) * | 2021-03-23 | 2023-11-01 | Neurophyxia B V | 2-Iminobiotin for use in the treatment of stroke |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20043214B (en) | 1999-01-21 | 2004-04-26 | Bristol Myers Squibb Company Us | Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same |
| US7087633B2 (en) | 2000-03-31 | 2006-08-08 | Universitair Medisch Centrum | Method for treating perinatal asphyxia in a human or animal neonate |
| DK1280526T3 (da) | 2000-03-31 | 2005-09-05 | Univ Medisch Centrum Utrecht | Anvendelse af 2-iminobiotin til fremstilling af et lægemiddel til forebyggelse og/eller behandling af komplikationer hos nyfödte som er opstået under födslen |
| US7319090B2 (en) | 2002-11-27 | 2008-01-15 | University Of North Carolina At Chapel Hill | Methods of treating cerebral ischemia |
| EP2076255A2 (en) | 2006-10-04 | 2009-07-08 | Neurokey A/S | Use of hypothermia inducing drugs |
| US9023878B2 (en) | 2010-05-26 | 2015-05-05 | Neurophyxia B.V. | 2-iminobiotin formulations and uses thereof |
| EP2852571A4 (en) * | 2012-05-23 | 2015-11-25 | Cellix Bio Private Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS |
| GB2504263B (en) | 2012-06-08 | 2015-09-16 | Gw Pharma Ltd | Synergistic therapies for neuroprotection |
| US10092591B2 (en) * | 2014-02-27 | 2018-10-09 | University Of Alaska Fairbanks | Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia |
| DK3389653T3 (da) * | 2015-12-16 | 2024-01-02 | Neurophyxia B V | 2-iminobiotin til anvendelse i behandling af hjernecellelæsion |
-
2016
- 2016-12-16 DK DK16825913.3T patent/DK3389653T3/da active
- 2016-12-16 AU AU2016372396A patent/AU2016372396B2/en active Active
- 2016-12-16 PL PL16825913.3T patent/PL3389653T3/pl unknown
- 2016-12-16 FI FIEP16825913.3T patent/FI3389653T3/fi active
- 2016-12-16 US US16/060,005 patent/US10525039B2/en active Active
- 2016-12-16 CA CA3008790A patent/CA3008790A1/en active Pending
- 2016-12-16 ES ES16825913T patent/ES2965754T3/es active Active
- 2016-12-16 EP EP16825913.3A patent/EP3389653B1/en active Active
- 2016-12-16 PT PT168259133T patent/PT3389653T/pt unknown
- 2016-12-16 JP JP2018551742A patent/JP6975165B2/ja active Active
- 2016-12-16 WO PCT/NL2016/050880 patent/WO2017105237A1/en not_active Ceased
-
2020
- 2020-01-03 US US16/734,226 patent/US10722496B2/en active Active
- 2020-07-10 US US16/926,123 patent/US11426387B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016372396B2 (en) | 2022-04-14 |
| AU2016372396A1 (en) | 2018-06-28 |
| US10525039B2 (en) | 2020-01-07 |
| US20200338046A1 (en) | 2020-10-29 |
| JP6975165B2 (ja) | 2021-12-01 |
| US10722496B2 (en) | 2020-07-28 |
| WO2017105237A1 (en) | 2017-06-22 |
| US11426387B2 (en) | 2022-08-30 |
| JP2019501969A (ja) | 2019-01-24 |
| FI3389653T3 (fi) | 2023-12-18 |
| CA3008790A1 (en) | 2017-06-22 |
| DK3389653T3 (da) | 2024-01-02 |
| ES2965754T3 (es) | 2024-04-16 |
| US20200147049A1 (en) | 2020-05-14 |
| EP3389653B1 (en) | 2023-11-08 |
| PT3389653T (pt) | 2023-12-28 |
| EP3389653A1 (en) | 2018-10-24 |
| US20190262316A1 (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201705673B (en) | Methods for treating skin | |
| PT3334422T (pt) | Utilização de ácido canabidiólico no tratamento de epilepsia | |
| GB201510664D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB201614522D0 (en) | Use of cannabinoids in the treatment of multiple myeloma | |
| SG10202007559PA (en) | Skin treatment apparatus | |
| AU364343S (en) | Skin toning device | |
| GB201403104D0 (en) | Skin treatment device | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| PL3215219T3 (pl) | System do zabiegów na skórze | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| SG11201704499WA (en) | Agent for hair deforming treatment | |
| SG11201704497PA (en) | Agent for hair deforming treatment | |
| PL3215157T3 (pl) | Apilimod do stosowania w leczeniu czerniaka | |
| HUE039750T2 (hu) | Hidroxi-buspiron mozgászavarok kezelésére | |
| IL276577A (en) | Methods for treating cardiac injury | |
| SG11201704504PA (en) | Agent for hair deforming treatment | |
| GB2553527B (en) | Headgear suitable for use in hydrotherapy | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| PL3389653T3 (pl) | 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych | |
| SG11201704493UA (en) | Agent for hair deforming treatment | |
| SMT202200221T1 (it) | Medicinale per l'uso nel trattamento della gotta | |
| GB201604658D0 (en) | Treatment for pain | |
| PL3291691T3 (pl) | Wykorzystanie azotanów w leczeniu poporodowej dysgalakcji u ssaków jednożołądkowych | |
| IL264600B (en) | A knife for use in medical treatment | |
| SG11201803077UA (en) | Cell treatment apparatus |